What We're Reading: Page 335
Industry reads hand-picked by our editors
May 19, 2016
-
Forbes
'Pay For Performance' Drug Plans Could Impact Biopharma's R&D Priorities
-
Reuters
Industry hits back at idea of pharma levy in superbug fight
-
Stat
As takeover talks drag on, Baxalta staff find themselves in merger limbo
-
Bloomberg Businessweek
The Real Reason Big Pharma Wants to Help Pay for Your Prescription
May 18, 2016
-
Reuters
Pascal Soriot's big experiment: reinventing AstraZeneca
-
Bloomberg
Valeant Said to Weigh Sale of Skin, Cancer Drugs to Cut Debt
-
Kaiser Health News
Three Firms Vie To Run CalPERS’ Drug Benefits
-
New York Times
Dogs Test Drug Aimed at Humans' Biggest Killer: Age
May 17, 2016
-
New York Times
Pfizer Could Get Its Money's Worth Out of Anacor Deal
-
Stat
Drug makers fuming at ‘overpriced’ values placed on their myeloma drugs
-
Forbes
Valeant Pharmaceuticals Hands Out Million Dollar Bonuses As Compensation For 'Challenging Times'
-
Reuters
Faced with shortages, Egypt lifts cheap drug prices by 20 percent
May 16, 2016
-
FiveThirtyEight
Theranos Is Wrong: We Don’t Need More Blood Tests
-
AP
Vermont to require drug makers to explain price increases
-
New York Times
Scientists Talk Privately About Creating a Synthetic Human Genome
-
Compare-Trials
Annals update protocol sharing requirements for trialists, after COMPare finds shortcomings
May 13, 2016
-
The Washington Post
Secret rebates, coupons and exclusions: How the battle over high drug prices is really being fought
-
The Verge
People used a journalism database to search for drugs
-
Stat
Why a FDA plan to find compassionate-use drugs may be a Band-Aid
-
CNN
Opioid history: From 'wonder drug' to abuse epidemic
May 12, 2016
-
BloombergGadfly
Pharma's Game of (Hep C) Thrones
-
Reuters
AstraZeneca drug wins orphan status in thyroid cancer
-
PharmaTimes
BMS bags two EU nods, for Empliciti and Opdivo/Yervoy
-
Food Dive
FDA posts final medical foods guidance amid category surge
May 11, 2016
-
HuffPost Business
Meet health care's major spoilers: Theranos, Valeant and Turing Pharmaceuticals
-
Stat
US senator introduces a 'Right to Try' bill for desperate patients
-
The New York Times
Change is in the air for pharmaceutical mergers
-
Research and Markets (via Business Wire)
Global contract pharmaceutical manufacturing market worth $84 billion by 2020
-
The Des Moines Register
Treating biopharma as 'boogeyman' is not the answer
Previous
